Targeted Drug Before Surgery for BRAF-Mutated Anaplastic Thyroid Cancer
Tests BRAF and MEK inhibitor drugs before surgery in adults with anaplastic thyroid cancer.
Key facts
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Where
- Leiden, NetherlandsSee the site
- Registry title
- NEOAC
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 21 Jan 2025
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional
- Record updated
- 17 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with anaplastic thyroid cancer that carries a BRAF V600E/K mutation, has not spread to distant organs, and has had no earlier cancer treatment.
- Age
- Over 18 years old
- Sex
- All sexes
- Disease stage
- Anaplastic thyroid cancer confirmed by tissue tests (centrally reviewed). No distant metastases (M0). Airway free or secured.
- Earlier treatment
- No earlier systemic cancer treatment (including chemotherapy, immunotherapy, oncolytic viral therapy). No earlier radiotherapy to the site of interest.
- Biomarker or test result
- BRAFV600E/K mutation confirmed in the primary tumor tissue.
Main reasons for not taking part
- Another cancer within 2 years before the ATC diagnosis (except basal cell skin cancer and in situ carcinoma)
- Poorly differentiated transformation of an earlier differentiated thyroid cancer
- Distant metastases
- Pregnancy or nursing
- Medical conditions that the investigator thinks would make treatment hazardous
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Informed consent
- No prior anticancer systemic treatment (including chemotherapy, immunotherapy, oncolytic viral therapy, other systemic therapies)
- No prior radiotherapy to site of interest
- Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥ 1.0x109/L, Platelets ≥ 100 x109/L, Hemoglobin ≥ 6.5 mmol/L, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, Total bilirubin ≤ 1.5 X ULN, INR and PTT in normal range, LDH < 2xULN. Serum creatinine ≤ 1.5 × ULN; or calculated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula; or estimated glomerular filtration rate > 50 mL/min/1.73m2
- Absence of additional severe and/or uncontrolled concurrent disease
- Age over 18 years old
- World Health Organization (WHO) Performance Status 0 or I
- Histologically confirmed ATC (centrally reviewed)
- Confirmed presence of BRAFV600E/K mutation in primary tumor tissue
- No distant metastases (M0)
- Free or secured airway
- Able to swallow pills
- Patients must have undergone complete disease staging including: PET-CT scan and CT-neck/thorax/abdomen
Who cannot take part
- Poorly differentiated transformation of previous differentiated thyroid cancer
- History of cancer within 2 years from diagnosis of ATC (exception: basal cell skin cancer, in situ carcinoma)
- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study treatment hazardous or obscure the interpretation of toxicity determination or adverse events
- History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes, significant arrhythmias and severe valvular disease must be evaluated for risks of undergoing general anesthesia
- No informed consent
- Presence of distant metastases
- Pregnancy or nursing
Where in Netherlands
- LUMCLeiden, NetherlandsTaking people
About the trial
What the trial wants to find out
This study aims to increase the number of patients that undergo a successful R0 tumor resection after neo-adjuvant BRAF/MEK inhibitor treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- (NEOAC) NEO- and Adjuvant Targeted therapy in braf-mutated Anaplastic Cancer of the Thyroid - a prospective, non-randomized, single center, open-label phase II study.
- Plain-language title
- Targeted Drug Before Surgery for BRAF-Mutated Anaplastic Thyroid CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 February 2025